On April 7, 2025, Glucosamine Sulfate Sodium Chloride (Application No.: CYHS2360915, Registration No.: Y20230001033) was approved for marketing as a chemical active pharmaceutical ingredient by the National Medical Products Administration (NMPA). The status on the Drug Master File (DMF) Registration Platform of the Center for Drug Evaluation (CDE) has been updated to "A".